期刊文献+

银杏叶胶囊联合阿立哌唑对精神分裂症患者认知功能的影响 被引量:27

Effects of Ginkgo Leaf Capsules (银杏叶胶囊) Combined with Aripiprazole on Cognitive Function of Patients with Schizophrenia
原文传递
导出
摘要 目的探讨银杏叶胶囊联合阿立哌唑治疗精神分裂症的临床疗效。方法 121例精神分裂症患者随机分为观察组和对照组各62例,对照组给予阿立哌唑口崩片,第1~4天每次5 mg,每日2次,从第5天开始每次10 mg,每日2次。观察组在对照组的基础上联合使用银杏叶胶囊每次0.25g,每日3次。两组均治疗12周。治疗前和治疗4、8、12周末进行PANSS量表、威斯康星卡片分类测验(WCST)、听觉注意测验(AAT)评分,并评价临床疗效。结果观察组总有效率为88.52%,对照组总有效率81.67%,两组比较差异无统计学意义(P〉0.05)。两组PANSS量表评分比较差异无统计学意义(P处理〉0.05)。治疗8周后,观察组WCST及AAT各项评分均较治疗前明显改善(P〈0.05),而对照组患者仅WSCT评分之总测验次数、持续错误数、随机错误数及ATT评分之正确总数及遗漏数明显改善(P〈0.05),且观察组WSCT评分之完成分类数及ATT评分之遗漏数优于对照组(P〈0.05);治疗12周两组WCST、AAT各项评分均较治疗前明显改善(P〈0.05),且观察组WSCT评分之总测验次数、随机错误数、完成分类数及ATT评分之正确总数、错误数及遗漏数均明显优于对照组(P〈0.05)。结论银杏叶胶囊联合阿立哌唑治疗精神分裂症疗效可靠,能改善患者认知功能。 Objective To explore the curative effects of Ginkgo Leaf Capsules( 银杏叶胶囊) combined with aripiprazole in the treatment of schizophrenia. Methods One hundred and twenty-one patients with schizophrenia were randomly divided into an observation group and a control group,with 62 cases in each. Both groups were given aripiprazole orally disintegrating tablet,5 mg each time,twice per day from the first to the fourth day,and 10 mg each time,twice every day from the fifth day. The observation group was added with Ginkgo Leaf Capsules,0. 25 g each time,three times per day. The two groups were both treated for 12 weeks. Evaluation was conducted with PANSS scale,Wisconsin Card Sorting Test( WCST) and auditory attention test( ATT) scale before treatment and on the 4th,8th,and 12 th weekends after treatment,and the clinical curative effects were also evaluated. Results The total effective rate was 88. 52% in the observation group while 81. 67% in the control group,with no significant difference between the two groups( P 〉0. 05). There was no significant difference in grading in PANSS scale between the two groups( P 〉0. 05). After 8-weeks treatment,all scales of WCST and AAT in the observation group improved remarkably compared with that before treatment( P 〈0. 05); But in the control group,only total trials,persistent errors and random errors in WSCT scale,total correct number and missing number in the ATT scale remarkably improved( P〈 0. 05); The complete classification number in WSCT scale and missing number in the ATT scale in the observation group were both superior to that in the control group( P〈 0. 05). After being treated for 12 weeks,all types of grading in WCST and AAT in both groups improved remarkably compared with that before treatment( P 〈0. 05). Total trials,random errors and complete classification number in WSCT scale,and total correct number,error number and missing number in ATT scale in the observation group were all remarkably superior to that in the control group( P〈 0. 05). Conclusion Ginkgo Leaf Capsules combined with aripiprazole has reliable effects in the treatment of schizophrenia,and could improve cognitive function of patients.
出处 《中医杂志》 CSCD 北大核心 2016年第18期1583-1586,共4页 Journal of Traditional Chinese Medicine
关键词 精神分裂症 银杏叶胶囊 阿立哌唑 认知功能 schizophrenia Ginkgo Leaf Capsules aripiprazole cognitive function
作者简介 通讯作者:xjliucn@VIP.sina.com
  • 相关文献

参考文献15

  • 1VOS T, FLAXMAN AD, NAGHAVI M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990 - 2010: a systematic analysis for the Global Burden of Disease Study 2010 [J]. Lancet,2012, 380(9859) :2163-2196.
  • 2JOHNSON I, BEN AO, KEBIR O. Evaluation of correlations between cognitive performances and clinical dimensions of schizophrenia [J]. Tunis Med,2009,87 (10) : 664 ~ 669.
  • 3MATSUI M, ARAI H, YONEZAWA M, et al. The effects of cognitive rehabilitation on social knowledge in patients withschizophrenia[J]. Appl Neuropsychol,2009,16 ( 3 ) : 158 - 164.
  • 4GOLD JM. Cognitive deficits as treatment targets in schiz- ophrenia [J]. Schizophrenia Res, 2004,72 ( 1 ) : 21 - 28.
  • 5KEEFE RS, EESLEY CE, POE M. Defining a congnitive funtion decrement in schizophrenia [J]. Biol Psychiatry, 2005,57 (6) :688 - 691.
  • 6DEKOSKY ST, FITZPATRICK A, IVES DG. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in pre- vention of dementia [J]. Contemp Clin Trials, 2006, 27 (3), 238-253.
  • 7American Psychiatric Association. Diagnostic and statistcal manual of mental disorders ( DSM-IV ) [M]. 4th. Washing- ton DC : American Psychiatric Association, 1994 : 16 - 17.
  • 8KAY SR, FISZBEIN A, OPLER LA. The positive and negative syndrome scale (PANSS) for schizophrenia [J]. Schizophr Bull, 1987,13 (2) :261 - 276.
  • 9GREVE KW. The WCST-64:a standardized short-form of the Wisconsin Card Sorting Test [J]. Clin Neuropsyehol, 2001,15 (2) :228 - 234.
  • 10LEUCHT S, DAVIS JM,ENGEL RR, et al. Definitions of response and remission in schizophrenia:recommendations for their use and their presentation [J]. Acta Psychiatr Scand Suppl,2009 (438) :7 - 14. doi : 10.11 ll/j. 1600 - 0447. 2008. 01308. x.

二级参考文献24

共引文献120

同被引文献253

引证文献27

二级引证文献208

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部